Cytokinetics has been granted a patent for compounds of Formula (I) and their pharmaceutical compositions, along with methods of use. The patent covers specific compounds and their derivatives for potential therapeutic applications. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of February 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical compounds for medical use
A recently granted patent (Publication Number: US11919909B2) discloses a range of compounds, including Compound 4 and Compound 18, for use in pharmaceutical compositions. These compositions consist of the compounds, their tautomers, or pharmaceutically acceptable salts, along with suitable excipients. The patent also covers methods for treating various heart diseases, such as hypertrophic cardiomyopathy and heart failure with preserved ejection fraction, by administering the disclosed compounds to patients in need.
Furthermore, the patent extends to treating diseases associated with hypertrophic cardiomyopathy, secondary left ventricular wall thickening, small left ventricular cavity, hyperdynamic left ventricular contraction, myocardial ischemia, and cardiac fibrosis. Additionally, the methods outlined in the patent encompass inhibiting cardiac sarcomeres by utilizing the disclosed compounds. The diseases and conditions targeted by these methods include Fabry's Disease, Danon Disease, Noonan Syndrome, muscular dystrophies, and glycogen storage diseases, among others. The patent provides a comprehensive framework for utilizing the disclosed compounds in the treatment and management of a wide range of cardiac and related conditions.
To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
